Literature DB >> 16909122

Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p.

N A L Cody1, V Ouellet, E N Manderson, M C J Quinn, A Filali-Mouhim, P Tellis, M Zietarska, D M Provencher, A-M Mes-Masson, M Chevrette, P N Tonin.   

Abstract

Multiple chromosome 3p tumor suppressor genes (TSG) have been proposed in the pathogenesis of ovarian cancer based on complex patterns of 3p loss. To attain functional evidence in support of TSGs and identify candidate regions, we applied a chromosome transfer method involving cell fusions of the tumorigenic OV90 human ovarian cancer cell line, monoallelic for 3p and an irradiated mouse cell line containing a human chromosome 3 in order to derive OV90 hybrids containing normal 3p fragments. The resulting hybrids showed complete or incomplete suppression of tumorigenicity in nude mouse xenograft assays, and varied in their ability to form colonies in soft agarose and three-dimensional spheroids in a manner consistent with alteration of their in vivo tumorigenic phenotypes. Expression microarray analysis identified a set of common differentially expressed genes, such as SPARC, DAB2 and VEGF, some of which have been shown implicated in ovarian cancer. Genotyping assays revealed that they harbored normal 3p fragments, some of which overlapped candidate TSG regions (3p25-p26, 3p24 and 3p14-pcen) identified previously in loss of heterozygosity analyses of ovarian cancers. However, only the 3p12-pcen region was acquired in common by all hybrids where expression microarray analysis identified differentially expressed genes. The correlation of 3p12-pcen transfer and tumor suppression with a concerted re-programming of the cellular transcriptome suggest that the putative TSG may have affected key underlying events in ovarian cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16909122     DOI: 10.1038/sj.onc.1209821

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

Review 1.  From vestigial to vestigial-like: the Drosophila gene that has taken wing.

Authors:  Emilie Simon; Corinne Faucheux; Alain Zider; Nadine Thézé; Pierre Thiébaud
Journal:  Dev Genes Evol       Date:  2016-04-26       Impact factor: 0.900

2.  Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.

Authors:  Naoto Hori; Kazuyuki Okada; Yuki Takakura; Hiroyuki Takano; Naoto Yamaguchi; Noritaka Yamaguchi
Journal:  J Biol Chem       Date:  2020-05-08       Impact factor: 5.157

3.  VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer.

Authors:  Karen Gambaro; Michael C J Quinn; Paulina M Wojnarowicz; Suzanna L Arcand; Manon de Ladurantaye; Véronique Barrès; Jean-Sébastien Ripeau; Ann M Killary; Elaine C Davis; Josée Lavoie; Diane M Provencher; Anne-Marie Mes-Masson; Mario Chevrette; Patricia N Tonin
Journal:  Mol Oncol       Date:  2013-01-16       Impact factor: 6.603

4.  Evaluation of cancer stemness in breast cancer and glioblastoma spheroids in vitro.

Authors:  Açelya Yilmazer
Journal:  3 Biotech       Date:  2018-08-28       Impact factor: 2.406

5.  Aberrant promoter methylation of SPARC in ovarian cancer.

Authors:  Matthew J Socha; Neveen Said; Yanshan Dai; Joseph Kwong; Preetha Ramalingam; Vuong Trieu; Neil Desai; Samuel C Mok; Kouros Motamed
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

6.  Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.

Authors:  Isabelle J Létourneau; Michael C J Quinn; Lu-Lin Wang; Lise Portelance; Katia Y Caceres; Louis Cyr; Nathalie Delvoye; Liliane Meunier; Manon de Ladurantaye; Zhen Shen; Suzanna L Arcand; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  BMC Cancer       Date:  2012-08-29       Impact factor: 4.430

7.  The chemiluminescence based Ziplex automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip expression profiles.

Authors:  Michael C J Quinn; Daniel J Wilson; Fiona Young; Adam A Dempsey; Suzanna L Arcand; Ashley H Birch; Paulina M Wojnarowicz; Diane Provencher; Anne-Marie Mes-Masson; David Englert; Patricia N Tonin
Journal:  J Transl Med       Date:  2009-07-06       Impact factor: 5.531

8.  SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion.

Authors:  Christopher K Yunker; William Golembieski; Nancy Lemke; Chad R Schultz; Simona Cazacu; Chaya Brodie; Sandra A Rempel
Journal:  Int J Cancer       Date:  2008-06-15       Impact factor: 7.396

9.  Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity.

Authors:  P Wojnarowicz; K Gambaro; M de Ladurantaye; M C J Quinn; D Provencher; A-M Mes-Masson; P N Tonin
Journal:  Oncogenesis       Date:  2012-09-10       Impact factor: 7.485

10.  Secreted protein acidic and rich in cysteine (SPARC) suppresses angiogenesis by down-regulating the expression of VEGF and MMP-7 in gastric cancer.

Authors:  Jun-Ling Zhang; Guo-Wei Chen; Yu-Cun Liu; Peng-Yuan Wang; Xin Wang; Yuan-Lian Wan; Jing Zhu; Hong-Qiao Gao; Jie Yin; Wei Wang; Mao-Lin Tian
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.